Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

NexImmune’s AIM™ Technology Enables Novel Adoptive Immunotherapy Approach for Cancer Treatment

Published: Friday, March 07, 2014
Last Updated: Friday, March 07, 2014
Bookmark and Share
New scientific publication by NexImmune co-founder Dr. Jonathan Schneck.

NexImmune has announced a new scientific publication by NexImmune co-founder Dr. Jonathan Schneck and colleagues that provides an important advance in the use of its proprietary Artificial Immune (AIM™) Technology for cellular therapy of cancer.

The study, published this week in ACS Nano, demonstrated the use of nanoparticle artificial Antigen Presenting Cells (aAPC), a key component of the AIM technology, with applied magnetic fields to activate and expand naive, normally poorly responsive T cell populations. Significantly, activated cells were highly effective for treating cancer in a mouse model system.

Activating naive T cells has been a key, but elusive goal of immunotherapy as these cells are more effective than differentiated T cell subtypes for treating cancer. Once activated, naive T cells have a higher proliferative capacity and a greater ability to generate strong, long-term T cell responses important for immunotherapy.

Thus, this study describes a novel approach whereby AIM aAPC can potentially be coupled to magnetic-field-enhanced activation of T cells to increase the yield and activity of antigen-specific T cells expanded from naive precursors, thereby improving cellular therapy for cancer.

CEO Kenneth Carter commented: “The publication in ACS Nano represents an important advance in the therapeutic potential of the AIM aAPC technology in adoptive cellular therapy involving direct ex-vivo stimulation of patient immune cells. T cells activated by aAPC in a magnetic field inhibited growth of B16 melanoma in mice with significantly improved host survival, thereby demonstrating the clinical relevance of the AIM technology for adoptive immunotherapy.”

The AIM aAPC platform is the foundation for an innovative approach to immunotherapy in which the body’s own immune system is guided by a synthetic particle engineered to activate and orchestrate a targeted immune response.

Central to the AIM technology are aAPC that bypass many of the bottlenecks related to both established and emerging immunotherapies.

AIM aAPC have potential uses as both ex vivo adoptive immunotherapies and as injectable off-the-shelf medicines. NexImmune, Inc. holds an exclusive worldwide license to the AIM aAPC technology from Johns Hopkins University.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

NexImmune Makes Appointments to its Board
Kenneth Carter, PhD and Professor Jonathan Schneck, MD, PhD, have been appointed company President and Chief Executive Officer and Chairman of the company's Clinical and Scientific Advisory Board, respectively.
Thursday, January 05, 2012
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!